Next week our scientists are visiting San Antonio for the annual Society of Toxicology (SOT) conference.
Here is a list of our activities at this year’s SOT.
Monday 12th March
Absence of in vitro mutagenic and genotoxic properties of two superficial tobacco extracts
Scott, K. Le Godec, T. Crooks, C. Allbutt, B. Nightingale, J. McAdam, K. Meredith, C.
15:00* – CC Exhibit Hall | 1506/P724
Tuesday 13th March
A highlight of this year’s SOT conference, our Chief Scientific Officer, Dr Chris Proctor, will be taking part in a roundtable event on the evaluations of next-generation nicotine products. Be there at 11:00am, this is not to be missed!
Alternative Toxicology Approaches to Evaluate Next-Generation Nicotine Products
Chairperson: Jack Fowle
Speakers: Erin Hill, Warren Casey, Thomas Hartung, Christopher Proctor
The in vitro biological assessment of a tobacco heating product and comparison with a cigarette smoke.
Breheny, D. Adamson, J. Bozhilova, S. Jaunky, T. Taylor, M. Santopietro, S. Terry, A. Thorne, D. Gaҫa, M.
13:30 – CC Exhibit Hall | 2371/P725
In vitro RNA-seq-based toxicogenomics assessment shows reduced biological effect of tobacco heating products when compared to cigarette smoke
Haswell, L. Corke, S. Jaunky, T. Santopietro, S. Baxter, A. Thorne, D. Minet, E. Gaça, M.
15:00 – CC Exhibit Hall | 1936/P269
The characterisation of a human two Organ-on-a-Chip (lung-liver) system which has the potential to measure systemic responses in vitro
Collaboration with CN Bio
Dalrymple, A. Kostrzewski, T. Maraver, P. Corke, S. Hughes, D. Gaca, M.
15:00 – CC Exhibit Hall | 2137/P474
We will be tweeting throughout the conference. Visit @BAT_Sci for updates!
Wednesday 14th March
An Integrated Multi-Organ Culture System to Evaluate Tobacco Extract Systemic Responses
Collaboration with IONTOX
Hibbard, N. Dalrymple, A. Corpus, B. Baxter, A. Gaca, M. McKim, J.
09:15 – CC Exhibit Hall | 3132/P760
The assessment of native undiluted e-cigarette aerosol in vitro using 3D reconstituted human airway epithelium
Bishop E. Haswell L. Adamson J. Costigan. S. Thorne D. Gaca M.
10:45 – CC Exhibit Hall | 2799/P321
Reversibility of in vitro biological effects in cigarette smoke- exposed 3D lung tissues following switching to a tobacco heating product
Haswell, L. Corke, S. Jaunky, T. Santopietro, S. Baxter, A. Thorne, D. Minet, E. Dalrymple, A. Gaça, M.
10:45 – CC Exhibit Hall | 2798/P320
Comparative in vitro toxicological evaluation of novel tobacco heating product
Thorne, D. Breheny, D. Kendall, B. Proctor, C. Gaca, M.
10:45 – CC Exhibit Hall | 2807/P329
Nicotine characterization of an in vitro inhalation exposure system using conventional and next generation tobacco products: a US/UK interlaboratory comparison
Collaboration with IIVS
Aragon, M. Adamson, J. Behrsing, H. Sheehan, D. Gaca, M. Raabe, H.
13:00 – CC Exhibit Hall | 2371/P725
Thursday 15th March
Cytotoxicity Response of Combustible Cigarette and Electronic Nicotine Delivery System in a 3D Human Oral Tissue Model
Collaboration with Reynolds American International
Keyser, B. Dalrymple, A. Thorne, D. Hollings, M. Seymour, A. Gaca, M. Fields, W.
08:30 – CC Hall 1 | P190
A clinical study investigating changes in exposure to cigarette smoke chemicals in Japanese smokers who switch to using a tobacco heating product for a five-day period
Gale, N. Hardie, G. McEwan, M. Eldridge, A. Errington, G. McDermott, S. Glew, J. Hedge, A. Murphy, J. Proctor, C. Fearon, I.
08:30 – CC Hall 1 | 3513/P303
A clinical study investigating changes in exposure to cigarette smoke chemicals in UK smokers who switch to using a tobacco heating product over a five-day period
McEwan, M. Gale, N. Eldridge, A. Errington. G. Graff. D. Murphy. J. Proctor. C. Fearon, I.
08:30 – CC Hall 1 | 3517/P307
An interlaboratory in vitro toxicological assessment of next generation nicotine delivery products (NGPs)
Collaboration with Japan Tobacco International
Ito, S. Taylor, M. Mori, S. Thorne, D. Oke, O. Bozhilova, S. Terry, A. Pop, R. Breheny, D. Yoshino, K. Gaca, M. Nishino, T. Proctor, C.
08:30 – CC Hall 1 | 3561/P353
Human In-Vitro Models for Respiratory Toxicology: Evaluation of Goblet Cell Hyperplasia, Mucus Production, and Ciliary Beating Assays
Collaboration with IIVS TWS
Aragon, M. Frentzel, S. Hoeng, J. Ito, S. Ishikawa, S. Budde, J. Maione, A. Hayden, P. Haswell, L. Azzopardi, D. Keyser, B. Fields, W. Behrsing, H.
08:30 – CC Hall 1 | 3220/P101
All poster materials will be fully available online after the event, however, be sure to come by
and meet us if you’re at the conference!
If however, you cannot attend, then keep an eye on our Twtter (@BAT_Sci) feed throughout the week for updates on all our activities.
*Please note all times are local – CST.
Notes to Editors
About British American Tobacco: British American Tobacco is a global tobacco and Next Generation Product company with brands sold in more than 200 markets. It employs more than 50,000 people worldwide and has over 200 brands in its portfolio, with its cigarettes chosen by one in eight of the world’s one billion smokers. Leading global brands include Dunhill, Kent, Pall Mall and Lucky Strike.
About Next Generation Products (NGP): Next Generation Products is part of the British American Tobacco Group and is focused on developing and delivering high-quality alternative nicotine and tobacco products for adult consumers in the key areas of Vapour, Oral and Tobacco Heating Products. For more information see www.goVype.com and www.bat-science.com.
About Tobacco Harm Reduction: The only way to avoid the risks associated with tobacco use is not to consume tobacco at all, and the best way to reduce the risks is to stop using tobacco. However, the concept of harm reduction is increasingly being considered in relation to tobacco use. Harm reduction is about finding practical ways to minimise the health impact of an inherently risky activity or behaviour, without seeking to stop it entirely. It is a key element of BAT’s business strategy and is being discussed by some regulators. We think it’s important to work towards producing consumer-acceptable, potentially reduced risk products. We believe that tobacco regulatory policies should include harm reduction approaches for the millions of adults globally who will continue to consume tobacco products.
The Public Health Impact of e-cigarettes: Many in the public health community believe e-cigarettes offer great potential for contributing to tobacco harm reduction policies. A 2018 updated evidence review by Public Health England*, an executive body of the UK Department of Health, concludes that vaping is around 95% less harmful than smoking cigarettes. The UK’s Royal College of Physicians have said that the public can be reassured that e-cigarettes are much safer than smoking and that they should be widely promoted as a substitute for smoking.
For more information: email Joanna_Hunt@bat.com or call +44 (0)7858 375461